, /PRNewswire/ — According to DataM Intelligence, the In-Silico Clinical Trials Market Size was USD 3.76 billion in 2023, increased to USD 3.95 billion in 2024, and is projected to…
, /PRNewswire/ — According to DataM Intelligence, the Intratumoral Cancer Therapies Market Size increased from USD 219.79 million in 2023 to USD 246.4 million in 2024, and is expected to…
La Agencia Europea de Medicamentos (EMA) otorga la designación de medicamento huérfano al tratamiento plasmático de Kedrion para la aceruloplasminemia congénita, un trastorno genético poco frecuente del metabolismo del hierro…
A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real time, alerting patients and caregivers minutes before an episode occurs1…
This designation marks a significant milestone for patients and reaffirms Kedrion’s commitment to addressing unmet medical needs in rare and ultra-rare diseases , /PRNewswire/ — Kedrion announces that the European…
, /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune…
, /PRNewswire/ — GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik’s team at Asan Medical Center has been published…
New addition strengthens SK Biopharmaceuticals’ radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration , /PRNewswire/ — SK Biopharmaceuticals, CO., Ltd., a biotech company…
, /PRNewswire/ — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased…
, /PRNewswire/ — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased…